Alkermes plc
NASDAQ:ALKSBiotechnology
+$0.79 today
- Market cap
- $7.87B
- Beta
- 0.33
- P/E (TTM)
- 49.1
- EPS (TTM)
- $0.92
Volume 1.39M
Average 2.33M
ALKS Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Alkermes plcNASDAQ: ALKS
Free Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Free cash flow growth accelerates
Q3 FY2026 free cash flow of $90.08M rose 6.8% year over year, ahead of the -53.7% change in trailing-twelve-month free cash flow. Sequentially, it fell 34.3% from the prior quarter.
Context
- Free cash flow amounted to 32.5% of revenue in FY2025, up 6.5 pp from a year earlier.
- Free cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +6.8% holds above the trailing-twelve-month pace of -53.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 480.33M USD
- Year-over-year change
- +18.4%
- 4-year CAGR
- +60.3%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 480.33M | +18.4% |
| FY2024 | 2024-12-31 | 405.64M | +14.8% |
| FY2023 | 2023-12-31 | 353.31M | +2152.8% |
| FY2022 | 2022-12-31 | (17.21M) | -123.7% |
| FY2021 | 2021-12-31 | 72.7M | — |
Free Cash Flow vs competitors
How ALKS compares with its peers on the latest reported figures
- ALKS's LTM Sep 2026 free cash flow of $227.37M is the 3rd largest of the 7 companies compared; the peer median is $96.59M.
- Its year-over-year change of -53.7% is the 6th highest of 7, against a peer median of +5.4%.
- Free cash flow amounts to 13.0% of revenue for ALKS, versus a peer median of 21.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.57B | +17.7% | +14.0% | 33.3% | |
| LTM Sep 2026 | $1.04B | +75.3% | +32.4% | 28.1% | |
| LTM Sep 2026 | $227.37M | -53.7% | — | 13.0% | |
| LTM Jun 2026 | $174.39M | -6.8% | — | 15.3% | |
| LTM Mar 2026 | $127.3M | +121.8% | — | 58.5% | |
| LTM Jun 2026 | $71.39M | -40.9% | -7.1% | 9.2% | |
| LTM Jun 2026 | $18.79M | -89.9% | -26.6% | 2.3% | |
| Peer median (excluding ALKS) | $96.59M | +5.4% | +3.4% | 21.7% | |
Competitors are the stored peer set for ALKS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (48.17M) | (158.27M) | 355.76M | 367.07M | 241.66M |
| Depreciation & Amortization | 78.65M | 77.86M | 74.93M | 28.53M | 27.17M |
| Deferred Income Tax | 5.08M | (32.8M) | (99.9M) | 40.52M | 28.77M |
| Stock-Based Compensation | 87.62M | 94.25M | 100.91M | 96.64M | 98.72M |
| Change in Working Capital | (25.55M) | 12.71M | (36.66M) | (98.15M) | 119.12M |
| Accounts Receivables | (38.01M) | 25.25M | (44.51M) | (56.34M) | 55.49M |
| Inventory | (24.77M) | (31.02M) | (2.71M) | 3.09M | (14.06M) |
| Accounts Payables | 43.31M | 15.53M | 23.01M | (57.97M) | 100.89M |
| Other Working Capital | (6.08M) | 2.95M | (12.45M) | 13.06M | (23.2M) |
| Other Non-Cash Items | 4.08M | 27.28M | 6.33M | 4.51M | 5.31M |
| Operating Cash Flow | 101.72M | 21.04M | 401.35M | 439.12M | 520.75M |
| Capital Expenditures | (29.02M) | (38.26M) | (48.05M) | (33.48M) | (40.42M) |
| Acquisitions (Net) | (713K) | 485K | 0 | 97.98M | 2.79M |
| Purchases of Investments | (340.42M) | (309.67M) | (254.47M) | (486.55M) | (364.37M) |
| Sales of Investments | 295.01M | 281.63M | 355.52M | 310.29M | 697.49M |
| Other Investing Activities | 8.94M | 1.27M | 354K | 461K | 0 |
| Investing Cash Flow | (66.2M) | (64.54M) | 53.36M | (111.31M) | 295.5M |
| Debt Repayment | 20.32M | (3M) | (3M) | (291.79M) | 0 |
| Common Stock Issued | 25.32M | 19.63M | 16.76M | 27.57M | 43.41M |
| Common Stock Repurchased | (16.57M) | (18.2M) | (28.47M) | (200.28M) | (31.03M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (275M) | (29.64M) | 0 |
| Financing Cash Flow | 29.07M | (1.57M) | (289.71M) | (494.14M) | 12.38M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 64.58M | (45.07M) | 165M | (166.32M) | 828.63M |
| Free Cash Flow | 72.7M | (17.21M) | 353.31M | 405.64M | 480.33M |
Alkermes plc
NASDAQ:ALKS
Intrinsic Alpha fair value
Locked
Current Price
$46.85
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.